Richard Benjamin Shares Results of The ReCePI Phase III Clinical Study
Richard Benjamin, Chief Medical Officer at Cerus Corporation, shared on LinkedIn:
”The results of the ReCePI Phase III clinical study are now published.
A hearty congratulations to the many contributors and patients who have advanced the field of pathogen reduction for red blood cells (RBCs).
While transfusions are generally considered safe, they are always at risk for newly emerging infections (think historically of HIV, WNV, Zika, etc.) and for threats that are not covered by current testing (e.g., bacteria, malaria, etc.).
Technologies are FDA-approved to safeguard platelet and plasma transfusions, leaving an obvious gap with the most commonly transfused RBC components.
This work is bringing RBC pathogen reduction to reality and would not have been possible without generous funding from BARDA, a US agency with true foresight to protect patients against future and current threats to transfusion safety.”
Read the full article here.
Article: Transfusion of Amustaline/Glutathione Pathogen-reduced Red Blood Cells in Cardiac Surgery: A Randomized Phase 3 Clinical Trial
Authors: Michael E. Sekela, Edward L. Snyder, Ian J. Welsby, Yoshiya Toyoda, Mohamed Alsammak, Neel R. Sodha, Thomas M. Beaver, J. Peter R. Pelletier, James D. Gorham, John S. McNeil, Roman M. Sniecinski, Ronald G. Pearl, Gregory A. Nuttall, Ravi Sarode, T. Brett Reece, Richard Benjamin, and the ReCePI Study Collaborators
Stay updated on all scientific advances with Hemostasis Today.
-
Dec 6, 2025, 18:02ASH25 Day 1: Don’t Miss The Highlights
-
Dec 6, 2025, 15:44Atul Gupta on Where The Healthcare Innovation is Headed
-
Dec 6, 2025, 15:22Nathan White on How Inflammation Contributes to Coagulopathy After Trauma
-
Dec 6, 2025, 15:02Anas Younes on AstraZeneca’s Aims in Blood Cancer to Be Presented at ASH25
-
Dec 6, 2025, 14:08David Alderman: ASH25 is Live
-
Dec 6, 2025, 13:53Isabelle Mahé Presents The Proposals from INNOVTE CAT Working Group
-
Dec 6, 2025, 11:50Steve Tuplin on Roche’s Mission at ASH25
-
Dec 6, 2025, 11:13Khaled Musallam on The Lancet Haematology Podcast: Your ASH25 Roadmap
-
Dec 6, 2025, 06:34Akshat Jain: It was Wonderful Hosting and Meeting Industry Leaders on Their Visit Down to Southern California